Skip Nav Destination
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Persistent neonatal thrombocytopenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopenic mothers
Issue Archive
July 30 2015
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Clinical Trials & Observations
Marie-Hélène Delfau-Larue,Wolfram Klapper,Françoise Berger,Fabrice Jardin,Josette Briere,Gilles Salles,Olivier Casasnovas,Pierre Feugier,Corinne Haioun,Vincent Ribrag,Catherine Thieblemont,Michael Unterhalt,Martin Dreyling,Elizabeth Macintyre,Christiane Pott,Olivier Hermine,Eva Hoster,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network,on behalf of the European Mantle Cell Lymphoma Network
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
Clinical Trials & Observations
Brief Report
Giovanni Palladini,Sajitha Sachchithanantham,Paolo Milani,Julian Gillmore,Andrea Foli,Helen Lachmann,Marco Basset,Philip Hawkins,Giampaolo Merlini,Ashutosh D. Wechalekar
GENE THERAPY
Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Brief Report
Garyfalia Karponi,Nikoletta Psatha,Carsten Werner Lederer,Jennifer Eileen Adair,Fani Zervou,Nikolaos Zogas,Marina Kleanthous,Constantinos Tsatalas,Achilles Anagnostopoulos,Michel Sadelain,Isabelle Rivière,George Stamatoyannopoulos,Evangelia Yannaki
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein
Haiying Qin,Monica Cho,Waleed Haso,Ling Zhang,Sarah K. Tasian,Htoo Zarni Oo,Gian Luca Negri,Yongshun Lin,Jizhong Zou,Barbara S. Mallon,Shannon Maude,David T. Teachey,David M. Barrett,Rimas J. Orentas,Mads Daugaard,Poul H. B. Sorensen,Stephan A. Grupp,Terry J. Fry
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
Persistent neonatal thrombocytopenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopenic mothers
Clinical Trials & Observations
Brief Report
Hagit Hauschner,Nurit Rosenberg,Uri Seligsohn,Rafael Mendelsohn,Aryeh Simmonds,Yakov Shiff,Yaakov Schachter,Shraga Aviner,Nechama Sharon
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation
Elmina Mammadova-Bach,Véronique Ollivier,Stéphane Loyau,Mathieu Schaff,Bénédicte Dumont,Rémi Favier,Geneviève Freyburger,Véronique Latger-Cannard,Bernhard Nieswandt,Christian Gachet,Pierre H. Mangin,Martine Jandrot-Perrus
BLOOD WORK
-
Cover Image
Cover Image
During platelet spreading, there is a substantial increase in the surface area of the plasma membrane. VAMP-7 binds the cytosolic surface of platelet granules and interacts with actin-binding proteins. Double immunofluorescence staining for actin (red) and VAMP-7 (green) demonstrates that VAMP-7 translocates to the periphery of the platelet during spreading. VAMP-7 in the platelet periphery facilitates membrane fusion that provides membrane to cover growing actin structures. See the article by Koseoglu et al on page 651.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals